Literature DB >> 12049492

Allometric scaling of xenobiotic clearance: uncertainty versus universality.

T M Hu1, W L Hayton.   

Abstract

Statistical analysis and Monte Carlo simulation were used to characterize uncertainty in the allometric exponent (b) of xenobiotic clearance (CL). CL values for 115 xenobiotics were from published studies in which at least 3 species were used for the purpose of interspecies comparison of pharmacokinetics. The b value for each xenobiotic was calculated along with its confidence interval (CI). For 24 xenobiotics (21%), there was no correlation between log CL and log body weight. For the other 91 cases, the mean +/- standard deviation of the b values was 0.74 +/- 0.16; range: 0.29 to 1.2. Most (81%) of these individual b values did not differ from either 0.67 or 0.75 at P = 0.05. When CL values for the subset of 91 substances were normalized to a common body weight coefficient (a), the b value for the 460 adjusted CL values was 0.74; the 99% CI was 0.71 to 0.76, which excluded 0.67. Monte Carlo simulation indicated that the wide range of observed b values could have resulted from random variability in CL values determined in a limited number of species, even though the underlying b value was 0.75. From the normalized CL values, four xenobiotic subgroups were examined: those that were (i) protein, and those that were (ii) eliminated mainly by renal excretion, (iii) by metabolism, or (iv) by renal excretion and metabolism combined. All subgroups except (ii) showed a b value not different from 0.75. The b value for the renal excretion subgroup (21 xenobiotics, 105 CL values) was 0.65, which differed from 0.75 but not from 0.67.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12049492      PMCID: PMC2751218          DOI: 10.1208/ps030429

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  95 in total

1.  Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling.

Authors:  E J van Hoogdalem; Y Soeishi; H Matsushima; S Higuchi
Journal:  J Pharm Sci       Date:  1997-10       Impact factor: 3.534

2.  Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.

Authors:  N A Grene-Lerouge; M I Bazin-Redureau; M Debray; J M Scherrmann
Journal:  Toxicol Appl Pharmacol       Date:  1996-05       Impact factor: 4.219

3.  Pharmacokinetics of procaterol in the rat, rabbit and beagle dog.

Authors:  M Ishigami; K Saburomaru; K Niino; M Kido; S Morita; G Miyamoto; H Kohri
Journal:  Arzneimittelforschung       Date:  1979

4.  Of mice and men and elephants: metabolic rate sets glomerular filtration rate.

Authors:  M A Singer
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

5.  Pharmacokinetic study of three synthetic AT-binding pentasaccharides in various animal species-extrapolation to humans.

Authors:  J P Hérault; F Donat; T Bàrzu; B Crépon; A Bernat; J C Lormeau; J M Herbert
Journal:  Blood Coagul Fibrinolysis       Date:  1997-04       Impact factor: 1.276

6.  Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration.

Authors:  C Lin; S Gupta; D Loebenberg; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.

Authors:  S P Khor; H Amyx; S T Davis; D Nelson; D P Baccanari; T Spector
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

8.  Comparative kinetics of sematilide in four species.

Authors:  P H Hinderling; C Dilea; T Koziol; G Millington
Journal:  Drug Metab Dispos       Date:  1993 Jul-Aug       Impact factor: 3.922

9.  Interspecies comparison of acivicin pharmacokinetics.

Authors:  J P McGovren; M G Williams; J C Stewart
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

Review 10.  Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.

Authors:  J Kawakami; K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1994-06
View more
  23 in total

1.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

Authors:  Yasuhiro Tsuda; Shinji Tatami; Norio Yamamura; Yusuke Tadayasu; Akiko Sarashina; Karl-Heinz Liesenfeld; Alexander Staab; Hans-Günter Schäfer; Ichiro Ieiri; Shun Higuchi
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Predicting pediatric age-matched weight and body mass index.

Authors:  Sherwin K B Sy; Eduardo Asin-Prieto; Hartmut Derendorf; Emil Samara
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

4.  Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro-In Vivo Comparisons.

Authors:  David J Wilkinson; Rosalind L Southall; Mingguang Li; Lisa M Wright; Lindsay J Corfield; Thomas A Heeley; Benjamin Bratby; Ranbir Mannu; Sarah L Johnson; Victoria Shaw; Holly L Friett; Louise A Blakeburn; John S Kendrick; Michael B Otteneder
Journal:  AAPS J       Date:  2017-05-04       Impact factor: 4.009

5.  Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

Authors:  Xiaowei Zang; Leonid Kagan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-04-18       Impact factor: 2.745

6.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.

Authors:  Zhiping Li; Yewei Chen; Qin Li; Di Cao; Wenjing Shi; Yun Cao; Dan Wu; Yiqing Zhu; Yi Wang; Chao Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-01-26       Impact factor: 2.953

8.  Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?

Authors:  Gary W Caldwell; John A Masucci; Zhengyin Yan; William Hageman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

9.  Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Authors:  Flora T Musuamba; Annick Rousseau; Jean-Louis Bosmans; Jean-Jacques Senessael; Jean Cumps; Pierre Marquet; Pierre Wallemacq; Roger K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.

Authors:  Zhe-Yi Hu; Jingtao Lu; Yuansheng Zhao
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.